This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07607587 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 114 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity; Overweight |
| Interventions | Cagrilintide; Placebo (matched to Cagrilintide) |
| Start | May 29, 2026 |
| Primary completion | Nov 19, 2027 |
| Study completion | Nov 19, 2027 |
| Results posted | Not yet |
| Registry last updated | Jun 25, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo | At week 26 |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
